Your browser is no longer supported. Please, upgrade your browser.
Vera Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.85 Insider Own0.95% Shs Outstand21.27M Perf Week-2.15%
Market Cap427.78M Forward P/E- EPS next Y-3.08 Insider Trans0.00% Shs Float20.77M Perf Month-5.19%
Income-58.60M PEG- EPS next Q-0.47 Inst Own80.60% Short Float1.17% Perf Quarter14.45%
Sales- P/S- EPS this Y-350.60% Inst Trans0.03% Short Ratio3.91 Perf Half Y9.58%
Book/sh4.02 P/B4.87 EPS next Y-25.70% ROA- Target Price49.67 Perf Year-
Cash/sh3.94 P/C4.96 EPS next 5Y- ROE- 52W Range11.30 - 37.11 Perf YTD-26.80%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-47.43% Beta-
Dividend %- Quick Ratio22.20 Sales past 5Y- Gross Margin- 52W Low72.65% ATR2.84
Employees15 Current Ratio22.20 Sales Q/Q- Oper. Margin- RSI (14)40.69 Volatility13.28% 13.83%
OptionableNo Debt/Eq0.00 EPS Q/Q-64.30% Profit Margin- Rel Volume0.30 Prev Close19.56
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume62.04K Price19.51
Recom1.70 SMA20-13.32% SMA50-20.42% SMA2001.02% Volume17,477 Change-0.26%
Jan-18-22 07:30AM  
Jan-04-22 07:30AM  
Dec-20-21 07:26PM  
Dec-17-21 07:54AM  
Dec-14-21 07:30AM  
Nov-10-21 04:15PM  
Nov-04-21 04:05PM  
Oct-13-21 07:30AM  
Sep-09-21 07:30AM  
Sep-07-21 04:58AM  
Aug-18-21 02:45PM  
Aug-16-21 07:30AM  
Jul-14-21 07:30AM  
Jun-24-21 07:15AM  
Jun-15-21 11:37AM  
May-27-21 04:05PM  
May-14-21 03:40PM  
May-13-21 08:52PM  
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.